Response to 'Do different treatment strategies of galcanezumab have similar effect on migraine?'

Author(s):
Goadsby, P.J.; Terwindt, G.M.; Ruff, D.D.; Ford, J.H.; Tockhorn-Heidenreich, A.; Stauffer, V.L.; Govindan, S.; Aurora, S.K.
Published
2020
Publication type
Article / Letter to editor
calcitonin gene-related peptideepisodic migraineGalcanezumabLY2951742phase 3preventive failure
Date issued
2020-03-02
Language
English
Publisher
WILEY
Is part of
hdl
1887/3182717
doi
10.1111/ene.14168